Back to top

Image: Bigstock

Is a Surprise Coming for Revance (RVNC) This Earnings Season?

Read MoreHide Full Article

Investors are always looking for stocks that are poised to beat at earnings season and Revance Therapeutics, Inc. (RVNC - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Revance is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for RVNC in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of $1.08 per share for RVNC, compared to a broader Zacks Consensus Estimate of a loss of $1.09 per share. This suggests that analysts have very recently bumped up their estimates for RVNC, giving the stock a Zacks Earnings ESP of +1.38% heading into earnings season.

Revance Therapeutics, Inc. Price and EPS Surprise

Revance Therapeutics, Inc. Price and EPS Surprise

Revance Therapeutics, Inc. price-eps-surprise | Revance Therapeutics, Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that RVNC has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Revance, and that a beat might be in the cards for the upcoming report.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Revance Therapeutics, Inc. (RVNC) - free report >>

Published in